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Abstract
Gastrointestinal stromal tumors (GISTs) are rare but treatable soft tissue sarcomas. Nearly all GISTs have somatic mutations
in either the KIT or PDGFRA gene, but there are no known inherited genetic risk factors. We assessed the relationship
between KIT/PDGFRA mutations and select deletions or single nucleotide polymorphisms (SNPs) in 279 participants from a
clinical trial of adjuvant imatinib mesylate. Given previous evidence that certain susceptibility loci and carcinogens are
associated with characteristic mutations, or ‘‘signatures’’ in other cancers, we hypothesized that the characteristic somatic
mutations in the KIT and PDGFRA genes in GIST tumors may similarly be mutational signatures that are causally linked to
specific mutagens or susceptibility loci. As previous epidemiologic studies suggest environmental risk factors such as dioxin
and radiation exposure may be linked to sarcomas, we chose 208 variants in 39 candidate genes related to DNA repair and
dioxin metabolism or response. We calculated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the
association between each variant and 7 categories of tumor mutation using logistic regression. We also evaluated gene-
level effects using the sequence kernel association test (SKAT). Although none of the association p-values were statistically
significant after adjustment for multiple comparisons, SNPs in CYP1B1 were strongly associated with KIT exon 11 codon 557-
8 deletions (OR = 1.9, 95% CI: 1.3-2.9 for rs2855658 and OR = 1.8, 95% CI: 1.2-2.7 for rs1056836) and wild type GISTs (OR = 2.7,
95% CI: 1.5-4.8 for rs1800440 and OR = 0.5, 95% CI: 0.3-0.9 for rs1056836). CYP1B1 was also associated with these mutations
categories in the SKAT analysis (p = 0.002 and p = 0.003, respectively). Other potential risk variants included GSTM1, RAD23B
and ERCC2. This preliminary analysis of inherited genetic risk factors for GIST offers some clues about the disease’s genetic
origins and provides a starting point for future candidate gene or gene-environment research.
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Introduction
Gastrointestinal stromal tumors (GISTs) are soft tissue sarcomas
that develop primarily in the stomach (60–70%) and small
intestines (20–30%), but also appear in the rectum, colon,
esophagus or omentum [1,2]. These tumors are quite rare, with
an estimated annual incidence of 6.8 cases per million individuals
in the US between 1992 and 2000 [3], and 3300 to 6000 new US
cases predicted each year [4], though systematic under-ascertain-
ment of GIST cases implies the true rate is slightly higher [3,5,6].
Data from the National Cancer Institute’s Surveillance, Epidemi-
ology and End Results (SEER) program suggest that GISTs are
more common in African-Americans than Caucasians (8.9 versus
4.5 cases per 1 million individuals per year, 1992-2002) but equally
common in men and women [5]. Median age at diagnosis in the
SEER population is 63 years.
Unlike other gastrointestinal neoplasms, more than 90% of
GISTs express the KIT proto-oncogene, as measured by immu-
nohistochemical analysis of CD117, the stem cell factor receptor
protein encoded by KIT [7,8]. In approximately 75% of GISTs,
this CD117 overexpression is attributable to a gain-in-function
mutation in the tyrosine kinase domain of KIT. Once mutated,
KIT may encode tyrosine kinase receptors in which the tyrosine
kinase domain can be activated in the absence of stem cell factor
signaling, thereby stimulating excess, unregulated proliferation of
the host tumor cells [8–10]. Another 10-15% of GISTs have
mutations in the PDGFRA gene, another tyrosine kinase receptor
encoding gene [8,11].
Primary GIST-related KIT and PDGFRA mutations have been
well characterized. Results from 3 population-based studies in
Switzerland [12], Norway [13] and France [14] suggest that 50-
60% of all GISTs have mutations in KIT exon 11, 5–10% in KIT
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exon 9, 3% in KIT exon 13, 1% in KIT exon 17, 2–5% in PDGFRA
exon 12 and 2–6% in PDGFRA exon 18. The proportions observed
in hospital-based or convenience samples are generally consistent
with these estimates, with some variability due to inclusion criteria
and small sample sizes [15–18].
Most GISTs with primary KIT or PDGFRA mutations respond
to treatment with imatinib mesylate (STI571, GleevecTM, Novartis
Pharmaceuticals, Basel, Switzerland), an inhibitor of the KIT and
PDGFRA tyrosine kinase. Imatinib is more effective in patients
with mutations in KIT exon 11 than in patients with no tumor
mutations (wild type) or exon 9 mutations [19,20]. Unfortunately,
roughly half of the patients who initially respond to imatinib
develop drug-resistant disease after prolonged treatment. This
acquired resistance may be attributable to the development of
secondary KIT mutations in residual tumor tissue [21–23].
While some KIT and PDGFRA germline mutations have been
identified among families with multiple GIST cases [24,25] and a
few studies have identified single nucleotide polymorphisms (SNPs)
associated with soft tissue sarcoma incidence (MDM2 [26]),
survival (AhR [27]), or specific translocations common in some
types of soft tissue sarcoma (XPG/ERCC5 [28]), no studies have
looked for inherited genetic risk factors for sporadic GISTs.
Though such studies are necessary to advance our understanding
of disease etiology, recruitment of cases and compatible controls is
limited by the disease’s rarity. A population-based study with rapid
case ascertainment and collection of detailed information on non-
genetic risk factors would be especially arduous, as GISTs are
often misclassified in reports to cancer surveillance systems [3,5,6].
Given these constraints, we decided to investigate the role of
inherited genetic polymorphisms in GIST development by
conducting a case-only analysis of the association between tumor
mutation type (mutations in KIT exon 11, KIT exon 9, PDGFRA,
or wild type) and 225 variants in 39 candidate genes using tumor
and blood samples collected during a phase III clinical trial of
adjuvant imatinib [29]. In previous studies, certain susceptibility
loci have been linked to characteristic tumor mutations, or
mutational ‘‘signatures’’. These include associations between
GSTM1-null genotype and TP53 transversion mutations among
bladder cancer patients [30], and certain functional polymor-
phisms in XPD and G:CRT:A TP53 mutations among lung
cancer patients [31]. Similarly, we hypothesized that the
characteristic somatic mutations in the KIT and PDGFRA genes
in GIST tumors may be mutational signatures that are causally
linked to specific mutagens or susceptibility loci. To address this
hypothesis, we selected candidate genes previously linked to soft
tissue sarcoma or to environmental risk factors for soft tissue
sarcoma. We included genes related to dioxin, phenoxyherbicide,
insecticide, vinyl chloride, and radiation response, as well as
variants in the previously identified AhR, MDM2, and ERCC5
genes [32–38]. We also looked at polymorphisms in genes
encoding proteins on the AhR/ARNT dioxin-response pathway
(CYP1A2, CYP1B1, HIF1A, NQO1, and G6PC/G6PT) [39–41],
other related metabolizing pathways (ADH1A, ADH1B, ADH1C,
ALDH18A1, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1,
ALDH1L1, ALDH1L2, ALDH2, CYP2B6, CYP2C8, CYP2C9,
CYP2D6, CYP2E1, CYP3A4, GSTM1, GSTT1, GSTP1, HNF4A,
NAT2, NFE2L2, NOS2A, PTGS2/COX2, and SULT1A1) [42–45]
and TP53, a tumor suppressor and cell cycle regulation gene
closely related to MDM2 [26]. Additionally, we selected several
DNA repair genes (ERCC2, RAD23B, XPA, and XPC) in the same
DNA repair pathway as ERCC5, as polymorphisms in these
nucleotide excision repair genes can affect individual sensitivity to
carcinogen-induced DNA damage [46]. As our main objective was
to conduct a preliminary assessment of these candidate genes
rather than any specific variants, we conducted gene-level as well
as SNP-level association analyses.
Materials and Methods
Study population
In total, 713 individuals participated in American College of
Surgeons Oncology Group (ACOSOG) Z9001, a multicenter,
phase III, randomized, double-blind study of adjuvant imatinib
(GleevecTM) versus placebo for patients with resected, primary
GISTs conducted between July 1, 2002 and April 18, 2007. Cases
were eligible if they had a localized tumor of at least 3 cm that
tested positive for CD117 by immunohistochemical analysis with
the Dako antibody (DakoCytomation, Copenhagen, Denmark).
Additional information on the Z9001 trial is published elsewhere
[29].
This genetic ancillary study includes the first 333 Z9001
participants who provided a blood sample and consented in
writing to unspecified future research using their blood and tumor
tissue samples. After removing individuals missing mutation data
(n = 52) or more than 10% of their genotype data (n = 2), 279
participants remained. Information on each participant’s race,
age, sex, and tumor size, site, stage, grade and mitotic rate was
available from the parent study. The study protocol was approved
by the Institutional Review Boards of Memorial Sloan-Kettering
Cancer Center and the University of North Carolina. All
participants provided written informed consent.
Variant selection
Once we selected our candidate genes, we identified single
nucleotide polymorphisms (SNPs) or deletions within those genes
that potentially affected function and had minor allele frequencies
(MAF) equal to or greater than 10% in the HapMap CEU
population [47]. This included nonsense, missense and splice site
mutations, as well as mutations in seed microRNA regions or
transcription binding sites. All selected nonsense, missense or splice
site mutations were in or near coding regions (within 2000 and 500
base pairs of the 59 and 39 ends of the region, respectively). SNPs
that did not pass the design phase (designability score ,1 or final
score ,0.7) were replaced with surrogate SNPs in high linkage
disequilibrium with the original candidate SNP.
Laboratory Analysis
During Z9001 enrollment, all tumor and blood specimens were
banked with the ACOSOG Central Specimen Bank at Washing-
ton University School of Medicine in St. Louis, Missouri, then
DNA extracted from these blood samples was sent to Memorial
Sloan-Kettering Cancer Center (MSKCC) for storage at 280uC
until analysis. Each sample was genotyped using the GoldenGate
genotyping assay (Illumina Inc., San Diego, CA) [48], which
consisted of allele-specific extension/ligation methodology fol-
lowed by universal primer polymerase chain reaction (PCR)
amplification regions for the candidate SNPs. Allele-specific oligos
and locus-specific oligos hybridized directly to the genomic DNA,
upstream and downstream from the targeted SNP before the
universal PCR reaction took place [49]. For internal quality
control purposes, twenty-seven participants underwent duplicate
genotype analysis. Concordance for duplicate samples was 99.9%.
SNPs were excluded if they were mono-allelic (n = 3), had a MAF
less than 5% in our study samples (n = 6), showed poor clustering
(n = 7), or had no individuals homozygous for the minor allele at
some levels of the outcome (n = 1), leaving 208 SNPs in the final
analysis.
Genetic Risk Factors for GISTs
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Deletions in GSTM1 and GSTT1 were detected using
multiplex PCR utilizing sets of target specific and housekeeping
gene specific primers [50]. Here, individuals with no copies of the
polymorphism of interest (null genotype) were differentiated from
those who had one or two copies (wild type).
DNA for mutation analysis was extracted from tumor tissue that
was snap-frozen and then analyzed as previously described
[15,51]. Briefly, all cases were first tested for KIT exon 11
mutations via PCR analysis using Platinum TaqDNA Polymerase
High Fidelity (Life Technologies, Inc., Gaithersburg, MD).
Tumors without exon 11 mutations were then subjected to PCR
analysis using primers for KIT exon 9, 13, 14 and 17 and PDGFRA
exon 12 and 18.
Statistical Analysis
Participants were categorized dichotomously based on the
presence or absence of a specific mutation type. The following
outcomes were considered: i) a deletion of KIT exon 11 codons
557–558, ii) any other (i.e. non-codon 557-8) KIT exon 11
deletion, iii) a KIT exon 11 insertion, iv) A KIT exon 11 point
mutation, v) a KIT exon 9, exon 13, exon 14, or exon 17 mutation,
vi) a PDGFRA exon 18 or 12 mutation, and vii) no KIT or PDGFRA
mutation (wild type). Although differentiation by non-exon 11 KIT
mutations would have been preferable, the prevalence of exon 9,
13, 14 and 17 mutations was too low for independent outcome
assessment.
We conducted descriptive analyses of selected demographic
variables and tumor characteristics, both overall and stratified by
gender and race (white vs. non-white). We also compared the
covariate distributions of our study population with the remaining
Z9001 trial participants to look for possible indications of bias. For
each variant, we calculated the race-specific MAF and Pearson x2
p-value for the association between genotype and race. We used
Fisher’s exact test when one or more cells had less than 5
observations. Additionally, we conducted a crude case-control
analysis by comparing the genotype distributions among the white
participants (n = 273) to the genotype distributions among
individuals of European descent using the HapMap database
[47]. Individuals with missing mutation data were included in
these descriptive analyses.
The association between germline polymorphisms and somatic
mutations was analyzed using logistic regression. We obtained
odds ratios (ORs), 95% confidence intervals (CIs) and p-values for
each SNP-mutation combination, adjusting for race, sex, and age
at diagnosis. We coded genotypes as ordinal variables (0 = homo-
zygous for the major allele, 1 = heterozygous, 2 = homozygous for
the minor allele) and estimated per-allele ORs and 1 df trend tests.
All p-values were corrected for multiple testing by controlling for
the false discovery rate [52].
Gene-level association tests were conducted using the sequence
kernel association test (SKAT) developed by Wu et al [53,54].
Here, SNPs are grouped based on prior biological knowledge, in
this case occurrence in the same gene, and analyzed using a
logistic kernel-machine-based multi-locus test. This method
requires fewer hypothesis tests than standard techniques and
improves power to detect the effect of an untyped, causal locus by
incorporating data from several correlated surrogate SNPs. This
method also allows for covariate adjustment, nonlinear effects, and
epistasis.
Briefly, this method uses a modified version of the variance
component score test to assess whether the variance of subject-
specific random effects differs from 0. The subject-specific model
for each of n individuals takes the form:
logit P(yi~1)~a0za1xi1z:::zamximzh(zi1,zi2,:::,zip),
where yi is the outcome for individual i, xi1 to xim are the covariate
values for individual i, a0 to am are the regression parameters, zi1
to zip are the genotypes for individual i at genotypes 1 to p, and
hi = h(zi1, z12,…zip) = h(Zi) =
Xn
i0~1
ci0K(Zi,Zi0 ) is a function for
the subject-specific random effect defined by a positive, definite
kernel function of the form K(N,N) and some ci, …, cn. Assuming h
follows an arbitrary distribution with a mean of 0 and variance tK,
testing the null hypothesis H0: h(Z) = 0 is equivalent to testing H0:
t= 0, which can be accomplished using a variance-component
score statistic [55]:
Q~
y{p̂0ð Þ’K y{p̂0ð Þ
2
where logit p̂0i~â0zâ1xi1zâ2xi2z:::zâmxim. To obtain a p-
value, we can compare Q to a scaled x2 distribution with scale
parameter k and degrees of freedom n, which are modified to
account for correlation between SNPs in the same SNP-set (for
further explanation, see Appendix A in Wu et al [54]). In this
analysis, we opted to use a kernel that models identity-by-state
(IBS), or the number of alleles shared by a pair of individuals. This
kernel is the most powerful option when epistatic effects may be
present.
Results
Descriptive analyses are shown in Table 1. The median age for
included participants was 58.0 years (range 18–85). Approximately
half of the population was male (51%) and the majority were white
(82%). Most tumors were located in the stomach (66%) or small
intestines (31%) and were between 5 and 10 cm in diameter.
70% of evaluated tumors had exon 11 KIT mutations, 10% had
PDGFRA mutations and 13% had no identified KIT or PDGFRA
mutations. Non-white participants were younger, on average (53.0
years vs. 59.0 years), and more likely to have stomach tumors (74%
vs. 64%) and exon 11 KIT mutations (84% vs. 67%). The most
common exon 11 KIT mutation was a deletion at codons 557–558
(34%).
Compared with other ACOSOG Z9001 participants, the
individuals included in this genotyping substudy have similar
demographic and tumor characteristics (Table 2). A somewhat
higher proportion of participants in this ancillary study were white
(82% versus 76%), but our subpopulation had nearly identical age,
gender, tumor size, mitotic rate, tumor location, and tumor
mutation type distributions to the full patient pool.
Genotype distributions of the 208 variants varied substantially
by race (Table S1), but genotype frequencies among whites in our
study population were very similar to the HapMap CEU sample
for the 204 SNPs available in both populations. Notable
discrepancies included SNPs on several aldehyde dehydrogenase
genes, ALDH1A3, ALDH1A2, ALDH1L1 and ALDH1L2, and two
DNA repair genes, ERCC2 and XPC.
The associations between each genetic variant and possible
outcome are depicted in Figure 1, with the strength of the
association quantified by the inverse of the log of the p-value.
While no SNPs were statistically significant after controlling for an
FDR level of 25%, some interesting patterns emerged. Most
notably, minor alleles at CYP1B1 rs1056836 and rs2855658 were
Genetic Risk Factors for GISTs
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e62119
positively associated with a deletion at KIT exon 11 codons 557-8
(OR = 1.81, 95% CI: 1.21–2.71 and OR = 1.91, 95% CI: 1.27–
2.86, respectively), while variation in another CYP1B1 SNP,
rs1800440, was positively associated with wild type tumors
(OR = 2.65, 95% CI: 1.48–4.76). Having a rare variant at
rs1056836 was inversely associated with wild type tumors
(OR = 0.54, 95% CI: 0.32–0.92).
Minor alleles in two RAD23B SNPs, rs7041137 and rs1805329,
were more common among tumors with KIT exon 9, 13, or 14
mutations (ORrs7041136 = 3.05, 95% CI: 1.52–6.12 and
ORrs1805329 = 3.24, 95% CI: 1.48–7.11) than tumors without such
mutations. The rare form of a third RAD23B SNP, rs1805334, was
also positively associated with non- exon 11 KIT mutations
(OR = 2.45, 95% CI: 1.16–5.14).
rs50872 in ERCC2 was the strongest risk factor for KIT exon 11
insertion mutations (OR = 2.68, 95% CI: 1.43–5.04) and the rare
variant of rs3815029 in GSTM1 was inversely associated with non-
codon 557-8 KIT exon 11 deletions (OR = 0.43, 95% CI:
Table 1. Demographic information and tumor characteristics of patients included in genotyping ancillary study.
Overall Sample Sex Stratified Race Stratified
N = 279 Male (n = 142) Female (n = 137) White (n = 229) Other (n = 50)
Age: Median (range) 58.0 (18–85) 57.0 (18–85) 58.0 (18–81) 59.0 (18–85) 53.0 (27–78)
Sex: N (%)
Male 142 (51) --- --- --- ---
Female 137 (49) --- --- --- ---
Race: N (%)
White 229 (82) 122 (86) 107 (78) --- ---
Other 50 (18) 20 (14) 30 (22) --- ---
Tumor Size: Median (range) 6.5 (3.0–37.0) 6.0 (3.0–37.0) 6.5 (3.0–28.0) 6.5 (3.0–37.0) 6.0 (3.1–30.0)
Tumor Size: N(%)
,5 cm 79 (28) 41 (29) 38 (28) 65 (28) 14 (28)
5-10 cm 146 (52) 72 (51) 74 (54) 119 (52) 27 (54)
.10 cm 54 (19) 29 (20) 25 (18) 45 (20) 9 (18)
Mitotic Rate: Median (range) 3 (0–351) 3 (0–351) 3 (0–207) 3 (0–351) 4.5 (0–81)
Mitotic Rate: N(%)
,5 156 (60) 77 (58) 79 (63) 132 (62) 24 (50)
$5 104 (40) 57 (42) 47 (37) 80 (38) 24 (50)
Missing 19 8 11 17 2
Tumor Location: N(%)
Stomach 182 (66) 97 (69) 85 (63) 146 (64) 36 (74)
Small Intestine 85 (31) 39 (28) 46 (34) 77 (34) 8 (16)
Rectum 2 (1) 1 (1) 1 (1) 1 (0) 1 (2)
Other 8 (3) 4 (3) 4 (3) 4 (2) 4 (8)
Missing 2 1 1 1 1
Mutation Type: N(%)
Exon 9 15 (5) 9 (6) 6 (4) 15 (7) 0 (0)
Exon 11 195 (70) 95 (67) 100 (73) 153 (67) 42 (84)
Exon 13 3 (1) 0 (0) 3 (2) 2 (1) 1 (2)
Exon 14 1 (0) 1 (1) 0 (0) 1 (0) 0 (0)
Exon 17 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PDGFRA 29 (10) 21 (15) 8 (6) 25 (11) 4 (8)
Wild type 36 (13) 16 (11) 20 (15) 33 (14) 3 (6)
Exon 11 mutation type: N(%)
557-8 deletion 66 (34) 33 (35) 33 (33) 51 (33) 15 (36)
Other deletion 45 (23) 25 (26) 20 (20) 34 (22) 11 (26)
Insertion 28 (14) 14 (15) 14 (14) 23 (15) 5 (12)
Point Mutation 56 (29) 23 (24) 33 (33) 45 (29) 11 (26)
PDGFRA mutation type: N(%)
D842V 12 (41) 10 (48) 2 (25) 10 (40) 2 (50)
Other 17 (59) 11 (52) 6 (75) 15 (60) 2 (50)
doi:10.1371/journal.pone.0062119.t001
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0.25,0.75). Based on the above evidence that at least one variant in
CYP1B1, RAD23B, ERCC2, or GSTM1 was associated with one or
more GIST mutation types at p,0.005, we provided a detailed
evaluation of the estimated effects for all of the variants in these
four key genes (Table 3). Effect estimates and p-values for the
remaining variants were included in Table S2. This table includes
results for rs4646755 in ALDH1L1 and rs3731149 in XPC, the
strongest risk factors for PDGFRA mutations and KIT exon 11
point mutations, respectively, both of which had p-values of 0.02.
These patterns were preserved in the gene-level SKAT analysis
(Figure 1, Table 4, and Table S3), with CYP1B1 again associated
with KIT exon 11 codon 557-8 deletions and wild type tumors
(p = 0.002 and 0.003, respectively); strong associations between
RAD23B and KIT exon 9, 13 or 14 mutations (p = 0.002); and
GSTM1 and non-codon 557-8 KIT exon 11 deletions (p = 0.01).
ALDH1L2 was also strongly associated with wild type tumors
(p = 0.01). As for the other three possible tumor subtypes, ALDH2
was associated with KIT exon 11 insertions (p = 0.03) and the null
Table 2. Comparison of patients included in the genetic ancillary study to the remainder of the Z9001 clinical trial patients.
Ancillary study (n = 279) Remaining Z9001 patients (n = 436)
Age: Median (range) 58.0 (18–85) 59.0 (21–91)
Sex: N (%)
Male 142 (51) 219 (50)
Female 137 (49) 217 (50)
Race: N (%)
White 229 (82) 332 (76)
Other 50 (18) 104 (24)
Tumor Size: Median (range) 6.5 (3.0–37.0) 6.6 (3.0–43.0)
Tumor Size: N(%)
,5 cm 79 (28) 118 (27)
5–10 cm 146 (52) 112 (49)
.10 cm 54 (19) 105 (24)
Mitotic Rate: Median (range) 3 (0–351) 3 (0–289)
Mitotic Rate: N(%)
,5 156 (60) 235 (65)
$5 104 (40) 126 (35)
Missing 19 75
Tumor Location: N(%)
Stomach 182 (66) 263 (61)
Small Intestine 85 (31) 142 (33)
Rectum 2 (1) 8 (2)
Other 8 (3) 22 (5)
Missing 1 2
Mutation Type: N(%)
Exon 9 15 (5) 20 (9)
Exon 11 195 (70) 148 (64)
Exon 13 3 (1) 6 (3)
Exon 14 1 (0) 0 (0)
Exon 17 0 (0) 1 (0)
PDGFRA 29 (10) 27 (12)
Wild type 36 (13) 28 (12)
Missing 0 206
Exon 11 mutation type: N(%)
557-8 deletion 66 (34) 41 (28)
Other deletion 45 (23) 34 (23)
Insertion 28 (14) 18 (12)
Point Mutation 56 (29) 55 (37)
PDGFRA mutation type: N(%)
D842V 12 (41) 15 (56)
Other 17 (59) 12 (44)
doi:10.1371/journal.pone.0062119.t002
Genetic Risk Factors for GISTs
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GSTT1 genotype was associated with PDGFRA-mutated tumors
(p = 0.04). No genes were associated with KIT exon 11 point
mutations (p,0.05).
Although the effect estimates were very imprecise, the
associations between the rare alleles of CYP1B1 SNPs rs1056836
and rs2855658 and KIT exon 11 codon 557-8 deletions were even
stronger when the analysis was limited to small intestinal tumors
(ORrs1056836 = 5.18, 95% CI: 2.07, 12.95 and ORrs2855658 = 5.17,
95% CI: 2.05, 13.03). Neither SNP was associated with the
outcome in stomach GISTs. No other clear patterns emerged in
site-specific subanalyses (data not shown).
Discussion
In this preliminary investigation of genetic risk factors for GIST
tumor subtypes we identified several genes and SNPs worthy of
further investigation. This included SNPs on two xenobiotic
metabolizing genes, CYP1B1 and GSTM1, and two DNA repair
genes, RAD23B and ERCC2. Further exploration of the relation-
ship between GISTs and aldehyde dehydrogenase genes or other
DNA repair genes (e.g. XPC), may also be warranted.
CYP1B1 encodes a cytochrome P450 enzyme that is involved
with phase I metabolism of PAHs, dioxin, and other chemicals
[43]. Two of the CYP1B1 SNPs we assessed have previously been
linked to cancer. This included the rare variant at rs1056836, a
missense mutation, which has been linked to increased risk of lung
cancer [56,57], multiple myeloma [39] and head and neck cancer
[58,59], with a possible inverse association with pancreatic cancer
[60]. Previous evaluations of the SNP’s association with breast,
colorectal, endometrial and prostate cancer have produced mostly
null findings [61–65]. The rare allele of rs1800440, another
missense mutation, was also associated with lung and head and
neck cancer [56,59], with no reported association with breast or
colorectal cancer [62,66]. However, this SNP did exhibit an
inverse association with endometrial cancer [61,65]. The remain-
ing CYP1B1 SNP, rs2855658, is located in a seed microRNA
region, but has no previously established links to cancer.
Although there is little evidence of a link between cancer and
the specific RAD23B, ERCC2, and GSTM1 variants identified here,
previous studies have observed associations between one or more
types of cancer and other variants on these three genes. For
example, SNPs in RAD23B have been linked to esophageal [67]
and bladder [68] cancers and one SNP near RAD23B was strongly
associated with breast cancer in a genome-wide association study
[69]. ERCC2 has also been linked to bladder cancer [68] and a
large meta-analysis completed in 2006 reported statistically
significant associations between ERCC2 SNPs and skin, breast
and lung cancer [70]. Neither RAD23B nor ERCC2 have been
linked to any type of sarcoma. Like the seed microRNA and
Figure 1. Log p-values for individual variant (left) and SKAT (right) analyses by functional group and tumor mutation type.
doi:10.1371/journal.pone.0062119.g001
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missense mutation SNPs in CYP1B1 that were strongly associated
with tumor mutations in the present study, some of the identified
RAD23B and ERCC2 SNPs also have potentially functional roles.
For example, rs13181 on ERCC2 is a missense mutation, as is
rs1805329 on RAD23B. Additionally, RAD23B’s rs1805330 is a
splice site mutation and rs10868 and rs1805334 are located on
transcription binding sites. As previously discussed, both RAD23B
and ERCC2 are nucleotide excision repair genes. Polymorphisms
in these and other DNA repair genes could impair an individual’s
DNA damage response and affect their carcinogen sensitivity [46].
GSTM1 is one of several genes encoding glutathione S-
transferases, which are phase II xenobiotic metabolizing enzymes
responsible for carcinogen activation or detoxification [45]. In
previous studies, GSTM1 deletions have been linked to osteosar-
coma incidence [71] and recurrence [72], with a non-statistically
significant positive association with soft tissue sarcoma mortality
[73]. Other studies of GSTM1 deletions have identified positive
associations between the null genotype and a variety of cancers,
included oral [45], colorectal [74], cervical [75], and bladder [76].
None of the association p-values were statistically significant
after adjustment for multiple comparisons, whether we applied a
false discovery rate correction of 25% or even 50%. While this
implies that the observed associations may be due to chance, it
should be noted that this was the first investigation of inherited risk
factors for GISTs and our main study purpose was to identify
variants worthy of further exploration. This study may also have
limited generalizability. Study subjects were drawn from a
predominantly white clinical trial population, and our findings
may not be applicable to other racial groups or to all
socioeconomic groups. As the HapMap CEU population is made
up of 60 parent-child trios, it may not be an adequate comparison
group for our population, especially since we were unable to adjust
for unequal distributions of age, gender or other potential
confounders.
Outcome misclassification is also a potential concern, as tumors
with KIT exon 11 mutations were not assessed for other KIT or
PDGFRA mutations and we did not test for PDGFRA exon 14
mutations in any tumors. However, previous reports suggest that
GISTs with 2 or more mutations are rare (,5%) [12,14], as are
PDGFRA exon 14 mutations (,1%) [11,77]. Thus, outcome
misclassification is unlikely to be a substantial source of bias. While
we have only limited evidence that our outcome classification
system corresponds to distinct carcinogenic processes in GISTs,
linking genetic polymorphisms to tumor phenotypes is valuable for
generating etiologic hypotheses [37,38].
In this small, yet novel, case-only study of genetic risk factors for
GIST tumor subtypes we identified several variants in CYP1B1,
RAD23B, GSTM1, and ERCC2 that we believe are worthy of
further investigation. We hope that this exploratory analysis serves
as a starting point for future research on genetic and environ-
mental causes of these rare and understudied tumors.
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